NO20065084L - Interferon-alfa polypeptider og konjugater - Google Patents
Interferon-alfa polypeptider og konjugaterInfo
- Publication number
- NO20065084L NO20065084L NO20065084A NO20065084A NO20065084L NO 20065084 L NO20065084 L NO 20065084L NO 20065084 A NO20065084 A NO 20065084A NO 20065084 A NO20065084 A NO 20065084A NO 20065084 L NO20065084 L NO 20065084L
- Authority
- NO
- Norway
- Prior art keywords
- conjugates
- polypeptides
- nucleic acids
- interferon
- alpha polypeptides
- Prior art date
Links
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57250404P | 2004-05-19 | 2004-05-19 | |
| PCT/US2005/017471 WO2005113592A2 (en) | 2004-05-19 | 2005-05-18 | Interferon-alpha polypeptides and conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20065084L true NO20065084L (no) | 2006-12-01 |
Family
ID=35428915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20065084A NO20065084L (no) | 2004-05-19 | 2006-11-03 | Interferon-alfa polypeptider og konjugater |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US7318918B2 (pt) |
| EP (1) | EP1753779A2 (pt) |
| JP (1) | JP2008507298A (pt) |
| CN (1) | CN101115769A (pt) |
| AR (1) | AR049177A1 (pt) |
| AU (1) | AU2005245918A1 (pt) |
| BR (1) | BRPI0511196A (pt) |
| CA (1) | CA2566247A1 (pt) |
| IL (1) | IL178470A0 (pt) |
| MX (1) | MXPA06013412A (pt) |
| NO (1) | NO20065084L (pt) |
| RU (1) | RU2006145020A (pt) |
| TW (1) | TW200611910A (pt) |
| WO (1) | WO2005113592A2 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040005673A1 (en) | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
| CA2360011A1 (en) | 1999-01-05 | 2000-07-13 | Trustees Of Boston University | Ordered gene assembly |
| US7435562B2 (en) | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
| US20030017552A1 (en) * | 2000-07-21 | 2003-01-23 | Jarrell Kevin A. | Modular vector systems |
| KR20070038462A (ko) * | 2004-05-12 | 2007-04-10 | 퓨전원 인코포레이티드 | 향상된 접속 인식 시스템 |
| CA2590245A1 (en) | 2004-11-11 | 2006-05-18 | Modular Genetics, Inc. | Ladder assembly and system for generating diversity |
| CA2597317C (en) * | 2005-03-09 | 2018-01-02 | Superlab Far East Limited | Uses of recombinant super-compound interferons |
| JP2008545393A (ja) | 2005-05-18 | 2008-12-18 | マキシジェン， インコーポレイテッド | 進歩したインターフェロンαポリペプチド |
| AR078117A1 (es) * | 2006-06-20 | 2011-10-19 | Protech Pharma S A | Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina |
| US20080014616A1 (en) * | 2006-07-11 | 2008-01-17 | Kevin Jarrell | Methods of introducing targeted diversity into nucleic acid molecules |
| JPWO2008013082A1 (ja) * | 2006-07-25 | 2009-12-17 | 株式会社ガルファーマ | ガレクチン９−ポリマーコンジュゲート |
| US7808342B2 (en) * | 2006-10-02 | 2010-10-05 | Skyworks Solutions, Inc. | Harmonic phase tuning filter for RF switches |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| WO2009006579A1 (en) * | 2007-07-05 | 2009-01-08 | Pharmaessentia Corp. | Peptide-polymer conjugates |
| EP2195338B1 (en) * | 2007-10-01 | 2013-12-25 | Pharmaessentia Corp. | N-terminal modified interferon-alpha |
| KR20100103595A (ko) * | 2008-01-18 | 2010-09-27 | 에프. 호프만-라 로슈 아게 | 비-글라이코실화된 단백질의 정제 |
| US7954022B2 (en) * | 2008-01-30 | 2011-05-31 | Alcatel-Lucent Usa Inc. | Apparatus and method for controlling dynamic modification of a scan path |
| AR074357A1 (es) * | 2008-11-17 | 2011-01-12 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro |
| US8940501B2 (en) | 2009-01-30 | 2015-01-27 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| BR112013031040A2 (pt) | 2011-06-02 | 2016-11-29 | Hanmi Science Co Ltd | multímero insulina-polímero não peptidil e método para a produção dos mesmos |
| WO2013003555A1 (en) | 2011-06-28 | 2013-01-03 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| CN102358897B (zh) * | 2011-10-31 | 2013-02-13 | 北京三元基因工程有限公司 | 重组人寡腺苷酸合成酶-1的制备方法 |
| EP3139955B1 (en) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusion proteins for treating cancer and related methods |
| EP3006045B3 (en) * | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
| IL299759A (en) | 2015-12-30 | 2023-03-01 | Genentech Inc | Formulations with reduced polysorbate dissolution |
| CN108883180B (zh) * | 2016-02-05 | 2023-07-07 | 奥里尼斯生物科学私人有限公司 | Clec9a结合剂及其用途 |
| RU2650755C1 (ru) * | 2017-05-24 | 2018-04-17 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С |
| WO2021150674A1 (en) * | 2020-01-24 | 2021-07-29 | Alkermes, Inc. | Methods of purification |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
| US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
| ES8302778A1 (es) | 1980-11-10 | 1983-02-01 | Genentech Inc | Un procedimiento para producir un polipeptido antiviral. |
| IT1167610B (it) | 1982-01-19 | 1987-05-13 | Cetus Corp | Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione |
| US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| JPS60152058A (ja) * | 1984-01-20 | 1985-08-10 | Toshiba Corp | 半導体記憶装置 |
| US4885166A (en) * | 1985-06-11 | 1989-12-05 | Ciba-Geigy Corporation | Hybrid interferons |
| US4695626A (en) * | 1986-07-29 | 1987-09-22 | Pfizer Inc. | 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| WO1992006707A1 (en) | 1990-10-17 | 1992-04-30 | Amgen Inc. | Methods and compositions for the treatment of cell proliferation disorders |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5574138A (en) * | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6007805A (en) | 1994-03-07 | 1999-12-28 | Imperial College Of Science And Technology | Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| DE69838552T2 (de) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
| ATE526401T1 (de) | 1999-01-14 | 2011-10-15 | Bolder Biotechnology Inc | Verfahren zur herstellung von proteinen mit freien cysteinresten |
| AU3725600A (en) | 1999-03-02 | 2000-09-21 | Maxygen, Inc. | Surrogate orphan ligands for orphan receptors |
| BR0010725A (pt) | 1999-05-19 | 2002-02-19 | Lexigen Pharm Corp | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc |
| US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
| WO2001025438A2 (en) | 1999-10-07 | 2001-04-12 | Maxygen, Inc. | Ifn-alpha homologues |
| KR20020065517A (ko) * | 1999-11-12 | 2002-08-13 | 맥시겐 홀딩스 리미티드 | 인터페론 감마 접합체 |
| CA2408851C (en) | 2000-05-16 | 2011-07-12 | Bolder Biotechnology, Inc. | Methods for refolding proteins containing free cysteine residues |
| WO2002044197A2 (en) | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
| KR100459105B1 (ko) | 2001-02-15 | 2004-12-03 | 선바이오(주) | 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체 |
| JP4279258B2 (ja) * | 2002-11-15 | 2009-06-17 | エフ．ホフマン−ラ ロシュ アーゲー | ＰＥＧ ＩＦＮアルファ２ａの位置異性体 |
| RU2005118998A (ru) * | 2002-11-18 | 2006-01-27 | Максиджен, Инк. (Us) | Полипептиды и конъюгаты альфа-интерферона |
-
2005
- 2005-05-18 BR BRPI0511196-0A patent/BRPI0511196A/pt not_active Application Discontinuation
- 2005-05-18 US US11/132,722 patent/US7318918B2/en not_active Expired - Fee Related
- 2005-05-18 EP EP05751765A patent/EP1753779A2/en not_active Withdrawn
- 2005-05-18 CA CA002566247A patent/CA2566247A1/en not_active Abandoned
- 2005-05-18 MX MXPA06013412A patent/MXPA06013412A/es unknown
- 2005-05-18 TW TW094116107A patent/TW200611910A/zh unknown
- 2005-05-18 RU RU2006145020/04A patent/RU2006145020A/ru unknown
- 2005-05-18 CN CNA2005800241473A patent/CN101115769A/zh active Pending
- 2005-05-18 WO PCT/US2005/017471 patent/WO2005113592A2/en not_active Ceased
- 2005-05-18 AU AU2005245918A patent/AU2005245918A1/en not_active Abandoned
- 2005-05-18 JP JP2007527427A patent/JP2008507298A/ja active Pending
- 2005-05-19 AR ARP050102059A patent/AR049177A1/es unknown
-
2006
- 2006-09-13 US US11/531,557 patent/US7531324B2/en not_active Expired - Fee Related
- 2006-09-13 US US11/531,531 patent/US7531630B2/en not_active Expired - Fee Related
- 2006-09-13 US US11/531,570 patent/US20070020734A1/en not_active Abandoned
- 2006-09-14 US US11/532,024 patent/US20070225204A1/en not_active Abandoned
- 2006-09-14 US US11/532,045 patent/US20070225205A1/en not_active Abandoned
- 2006-10-05 IL IL178470A patent/IL178470A0/en unknown
- 2006-11-03 NO NO20065084A patent/NO20065084L/no unknown
-
2007
- 2007-05-04 US US11/744,424 patent/US7541436B2/en not_active Expired - Fee Related
- 2007-08-14 US US11/838,730 patent/US7541163B2/en not_active Expired - Fee Related
- 2007-08-15 US US11/839,493 patent/US7537755B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20080171363A1 (en) | 2008-07-17 |
| WO2005113592A2 (en) | 2005-12-01 |
| US20070025966A1 (en) | 2007-02-01 |
| JP2008507298A (ja) | 2008-03-13 |
| US20080076710A1 (en) | 2008-03-27 |
| US20070225204A1 (en) | 2007-09-27 |
| US7541163B2 (en) | 2009-06-02 |
| EP1753779A2 (en) | 2007-02-21 |
| MXPA06013412A (es) | 2007-01-23 |
| US7531324B2 (en) | 2009-05-12 |
| AR049177A1 (es) | 2006-07-05 |
| US20070020734A1 (en) | 2007-01-25 |
| RU2006145020A (ru) | 2008-06-27 |
| US20050266465A1 (en) | 2005-12-01 |
| US20070020235A1 (en) | 2007-01-25 |
| US7537755B2 (en) | 2009-05-26 |
| AU2005245918A1 (en) | 2005-12-01 |
| WO2005113592A3 (en) | 2006-04-06 |
| BRPI0511196A (pt) | 2007-12-04 |
| IL178470A0 (en) | 2007-02-11 |
| US7541436B2 (en) | 2009-06-02 |
| US7318918B2 (en) | 2008-01-15 |
| US7531630B2 (en) | 2009-05-12 |
| TW200611910A (en) | 2006-04-16 |
| CA2566247A1 (en) | 2005-12-01 |
| CN101115769A (zh) | 2008-01-30 |
| US20070225205A1 (en) | 2007-09-27 |
| US20080031853A1 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20065084L (no) | Interferon-alfa polypeptider og konjugater | |
| NO20052363L (no) | Interferon-alfa polypeptider og konjugater | |
| WO2006083276A3 (en) | Interferon-alpha polypeptides and conjugates | |
| WO2004029219A3 (en) | Cell-based rna interference and related methods and compositions | |
| WO2004062475A3 (en) | Fluorescent assays for protein kinases | |
| WO2005121331A3 (en) | Truncated galnact2 polypeptides and nucleic acids | |
| WO2006055689A3 (en) | Protein scaffolds and uses thereof | |
| ATE353955T1 (de) | Durch zelloberflächenmoleküle induzierte makrophagenaktivierung | |
| DK1409459T3 (da) | ECL mærker, som har forbedrede, non-specifikke bindingsegenskaber, fremgangsmåder til anvendelse deraf, og kits indeholdende samme. | |
| NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
| NO20043564L (no) | Follistatindomene som inneholder proteiner | |
| WO2004078120A3 (en) | Collagen compositions and biomaterials | |
| WO2006017538A3 (en) | Hk1-binding proteins | |
| WO2005084305A3 (en) | Flavonoids | |
| DK1131444T3 (da) | Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse | |
| WO2004061122A3 (en) | Cell proliferation-related polypeptides and uses therefor | |
| NO20062709L (no) | Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller | |
| WO2007044083A3 (en) | Evolved interferon-alpha polypeptides | |
| WO2008094945A3 (en) | Compounds and methods for modulating protein expression | |
| WO2004007664A3 (en) | Nucleic acid vectors | |
| WO2005087793A3 (en) | Immunostimulatory compositions and uses thereof | |
| WO2003062453A3 (en) | Polycystic kidney disease nucleic acids and proteins | |
| WO2005103229A3 (en) | Transgenomic mitochondria, transmitochondrial cells and organisms, and methods of making and using | |
| WO2006063028A3 (en) | Immunostimulatory compositions and uses thereof | |
| WO2003062386A3 (en) | Syndecans and angiogenesis |